SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-304021
Filing Date
2023-12-27
Accepted
2023-12-27 16:41:58
Documents
12
Period of Report
2023-12-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d100894d8k.htm   iXBRL 8-K 23192
  Complete submission text file 0001193125-23-304021.txt   147953

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA awh-20231221.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE awh-20231221_lab.xml EX-101.LAB 18758
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE awh-20231221_pre.xml EX-101.PRE 11716
6 EXTRACTED XBRL INSTANCE DOCUMENT d100894d8k_htm.xml XML 3577
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 231518423
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)